Navigation Links
Treatment with anti-anemia drugs may not be safe for multiple myeloma patients
Date:8/4/2008

Thessaloniki, Greece - August 4, 2008 - A recent study published in American Journal of Hematology demonstrated that Erythropoiesis-stimulating agents (ESAs), a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients. In the study, 323 multiple myeloma patients were evaluated over a 20 year period in Greece from 1988 to 2007. The investigators reviewed their medical records and observed an association between ESA exposure and a reduction in progression-free and overall survival.

The study demonstrated that ESA administration may influence the course of the disease, in that people who received ESA may progress earlier than those who did not receive ESA. The median survival rate was 31 months for patients who were administered ESAs, compared to 67 months in those who were not exposed to ESAs. The median progression-free survival for patients in the ESA group was 14 months, and 30 months for those without ESA exposure.

For the past 15 years, erythropoiesis-stimulating agents have been used in the management of cancer-related anemia, but researcher Eirini Katodritou stresses the possible harmful effects ESAs may have on cancer patients. "Physicians should use ESAs with caution, based on the International Guidelines for ESA administration in cancer and on certain prognostic indicators to guide their use. Physicians need to identify the appropriate group of cancer patients who will benefit from ESA administration, while avoiding possible detrimental effects," said Katodritou.

The question of whether ESAs are harmful in patients with myeloma is a pressing clinical issue with at least eight prospective controlled clinical trials in the last five years reporting poorer outcomes with ESA use in patients with cancer, according to Dr. David P. Steensma of the Mayo Clinic. However, only two of those studies included some patients with myeloma. Dr. Steensma pointed out that the patients in the retrospective Greek study were imbalanced for many of the known prognostic markers in myeloma, indicating that sicker patients were given ESAs preferentially and that this group would have been predicted to do more poorly anyway. Although this imbalance might explain the results, Dr. Steensma discussed the importance of additional prospective studies of ESA safety in myeloma and other forms of cancer.


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide ... we as a society can control and change. , As nearly 795,000 Americans suffering ... seconds within the United States. Plus, with an estimated 129,000 of these people dying ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology: